Abstract
Beta-blocker therapy improves survival for CKD patients with cardiovascular disease (CVD). The incidence of CVD in Japanese CKD patients is lower than that of the U.S. The history of CVD and selection of antihypertension agents can play an important role in CVD prevention; however, the difference in the prescription patterns between the U.S. and Japan, and the contributing factors for the prescription of β-blocker in CKD patients have not been sufficiently elucidated. The aim of this study was to compare the prevalence of CVD and the prescription of β-blockers, using the well-established nationwide cohort studies in the U.S.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
